Who We Are
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments to treat hematological malignancies and prostate cancer across multiple modalities. The pipeline includes these investigational product candidates:
- ONCT-808, an autologous CAR T cell therapy that targets ROR1, as a targeted therapy for patients with multiple hematologic and solid malignancies, currently in Phase 1/2 development in patients with advanced B-Cell malignancies, including patients who have failed previous CD19 CAR T treatment.
- ONCT-534, a Dual-Action Androgen Receptor Inhibitor (DAARI), as a targeted therapy for patients with advanced prostate cancer resistant to available therapies, has completed IND-enabling studies.
- Zilovertamab, a monoclonal antibody that inhibits the ROR1 protein that is highly expressed in multiple hematologic and solid malignancies.
Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
